United Therapeutics Announces First Clinical Xenotransplant in EXTEND Study

11/20/2026
Impact: 65
Healthcare

United Therapeutics announced the first clinical xenotransplant in its EXTEND study, which is evaluating the safety and efficacy of its UThymoKidney in patients with end-stage renal disease. The procedure was performed at NYU Langone Health, with the study targeting patients who are ineligible for conventional kidney transplantation or need alternative treatment options. The company described the milestone as a step forward in its organ-manufacturing and xenotransplantation research; the article reported no financial results or stock-price impact.

AI summary, not financial advice

Share: